Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52).

Guidance

Financial Outlook: The Company believes that, based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements through Q4 2027. This outlook excludes any potential revenue from product sales, the potential monetization of a PRV, if received, or other non-operating sources of capital.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.